New drug combo shows promise for Tough-to-Treat lymphoma
NCT ID NCT02232516
First seen Jun 18, 2026 · Last updated Jun 18, 2026
Summary
This study tested a combination of two drugs, romidepsin and lenalidomide, in 30 adults with a rare and aggressive blood cancer called peripheral T-cell lymphoma (PTCL) who had not received prior treatment. The goal was to see if this drug pair could shrink tumors safely, since standard treatments often cause severe side effects and are not very effective. Participants received romidepsin through a vein and lenalidomide as a pill, and their response was tracked with imaging scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Weill Cornell Medicine
New York, New York, 10021, United States
-
Yale University
New Haven, Connecticut, 06520, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.